TCTR20230424002CompletedPhase 4
SARS-CoV-2 antibody response after a booster dose of the mRNA COVID-19 vaccine (BNT162b2) among Thai children and adolescents aged 5-17 years.
Siriraj Grant for Research Development0 sites150 target enrollmentStarted: April 24, 2023Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 150
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 5 Years to 17 Years (—)
- Sex
- All
Inclusion Criteria
- •1. The subject is aged 5 to less than 18 years. 2. Have received two doses of full dose mRNA COVID-19 vaccine 3. Have received 2nd dose of COVID-19 vaccine for at least 3 months at the time of third vaccination 4. Have no history of detecting SARS-CoV-2 infection 5. Can understand Thai language through speaking, reading, and writing 6. Capable of attending all study visits according to the study schedule
Exclusion Criteria
- •1. Have any history of severe drug or vaccine allergy (anaphylaxis) 2. Have a history of Myocarditis or pericarditis from the mRNA COVID-19 vaccine 3. Have received any other vaccines within 14 days for live vaccines or 28 days for inactivated vaccines (excepted influenza vaccine) 4. Have body temperature more than equal 38 C or 100.4 F within 24 hours prior received study vaccine 5. Subject who are pregnant 6. Have received blood transfusion, plasma, blood product, blood components, immunoglobulins, antiviral, or antibodies within the last 90 days 7. Have any history of immunodeficiency or received immunosuppressants or received steroids drugs 8. Have any conditions that are considered unsuitable for clinical study by the investigator
Investigators
Similar Trials
Completed
Not Applicable
Changes in antibody titer after SARS-CoV-2 vaccination of patients with in-center and home dialysisJPRN-UMIN000046281Reiseikai Medical Corporation Shinagawa Garden Clinic96
Not yet recruiting
Not Applicable
Can vaccination produce protective antibodies in people who fail to develop protective antibodies after recovery from COVID-19 infectioCTRI/2021/04/032572Rajiv Gandhi Cancer Institute and Research Centre
Not yet recruiting
Not Applicable
A study on post- vaccination IgG antibody status among the healthcare workersCTRI/2021/03/031986Rajarajeswari medical college and hoapital
Completed
Phase 4
Intradermal second booster COVID-19 vaccinatioThe second booster intradermal mRNA-based vaccine following the 2-dose primary series of ChAdOx1 (AstraZeneca) can provide a sufficient level of immunity against SAR-CoV-2.booster vaccine, SAR-CoV2, older adult, intradermal vaccination, elderly, ThailandTCTR20230411008Faculty of Medicine Siriraj hospital, Mahidol University107
Active, not recruiting
Phase 1
Study to Evaluate the Immune Response after a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-004461-41-Outside-EU/EEASanofi Pasteur Inc570